Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

Despite Global Increase in Amjevita Sales, US Sales Dropped 63%

August 5th 2023

By Skylar Jeremias

Despite global sales for Amjevita (adalimumab-atto) growing by 29% year-over-year and the agent being the first adalimumab biosimilar on the US market, sales in the United States dropped 63% from the first quarter to the second quarter of 2023.

The Top 5 Biosimilar Articles for the Week of July 31

August 4th 2023

By Justina Petrullo

Here are the top 5 biosimilar articles for the week of July 31, 2023.

Eye on Pharma: Interchangeability Study Results; Express Scripts to Cover Cyltezo; TDM for Idacio

August 3rd 2023

By Skylar Jeremias

Samsung Bioepis and Organon released results from an interchangeability study of its adalimumab biosimilar; Express Scripts announced that it will add Cyltezo as well as 2 other adalimumab biosimilars to its formulary list; Anser Therapeutics will offer therapeutic drug monitoring (TDM) for Idacio.

Link Between Antidrug Antibodies, Nonresponse to bMARDs in Patients With RA

August 2nd 2023

By Justina Petrullo

A link is suggested between antidrug antibodies and nonresponse to biologic disease-modifying antirheumatic drugs (bMARDs) in patients with rheumatoid arthritis (RA).

Biosimilars Immunology Roundup: July 2023

August 1st 2023

By Skylar Jeremias

Between the launch of 7 adalimumab biosimilars, the release of several market trend reports, and clinical trial results on often ignored disease states, July was a very big month for immunology biosimilars.

Patient and Provider Education on Biosimilars

August 1st 2023

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options.

Interchangeability In Biosimilars

August 1st 2023

Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study.

Abstracts Highlight Growing Comfortability With Trastuzumab Biosimilars in Breast Cancer

July 31st 2023

By Skylar Jeremias

Abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) emphasized the safety and efficacy of a trastuzumab biosimilar in treating HER2-positive breast cancer and growing utilization of trastuzumab biosimilars over time.

Why Are Companies Launching Biosimilars With 2 Prices? Julie Reed Explains

July 30th 2023

By Skylar Jeremias

Why are companies pricing their adalimumab biosimilars with 2 prices? Can the United States expect more of this pricing strategy for future biosimilar launches? Julie Reed, executive director of the Biosimilars Forum, has the answers.

Price Reductions of TNF Inhibitors Across Europe After First and Second Biosimilar Launches

July 29th 2023

By Deana Ferreri, PhD

Authors of a study examined changes in pricing, market share, and utilization of the tumor necrosis factor (TNF)–α inhibitors infliximab, etanercept, and adalimumab as the first and second biosimilars for each molecule were introduced in Europe.